Results 91 to 100 of about 4,767 (196)

Arming vaccinia virus for pancreatic cancer oncolytic virotherapy

, 2011
PhDVaccinia virus is a 250-300nm enveloped DNA virus from the poxvirus family and is used as a vector for oncolytic viral gene therapy. No unique cell surface receptor has been identified for Vaccinia virus and the reasons for its tropism for cancer ...
Hiley, Crispin
core  

Functional Genomic Studies of Vaccinia Virus Provide Fundamental Insights into Virus-Host Interactions

, 2017
The oncolytic virus field is in the midst of strong and sustained growth. The clinical utility of this class of therapeutics has been bolstered in recent years by the rise of immune checkpoint inhibition, which has the potential to work synergistically ...
Keller, Brian Andrew
core   +1 more source

CXC Chemokine‐Driven Vascular Reprogramming: Modulating Tumor Vasculature to Boost Therapeutic Response

Advanced Science, Volume 13, Issue 11, 23 February 2026.
Tumor vascular remodeling is discussed from a chemokine‐centered perspective. This review summarizes the bidirectional, temporal, and tissue‐specific roles of CXC chemokines in regulating vascular function and immune accessibility. A functional vascular normalization score is introduced as a conceptual framework to integrate dynamic vascular and immune
Hongdan Chen, Yinde Huang, Juntong Wu, Ziying Yi, Yao Li, Zeyu Yang, Fan Zhang, Chong Li   +7 more
wiley   +1 more source

Assessment and development of adenovirus type 11 for cancer therapy

, 2010
PhDThe efficacy of oncolytic virotherapy is influenced by the interactions between the tumour, virus and host immunity. The first generation of oncolytic adenoviruses, based on serotype 5 (Ad5), has achieved limited success in clinical trials.
Wong, Han Hsi
core  

Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68 [PDF]

, 2010
Canine mammary carcinoma is a highly metastatic tumor that is poorly responsive to available treatment. Therefore, there is an urgent need to identify novel agents for therapy of this disease.
Jochen Stritzker, Aladar A. Szalay, Michael Hess, Yong A. Yu, Ulrike Donat, Jörn Bullerdiek, Nanhai Chen, Ingo Nolte, Qian Zhang, Ivaylo Gentschev, Klaas Ehrig, Stephan Rudolph   +11 more
core   +1 more source

Crosstalk Between Intratumoral Microbes and Tumor Immunity: Implications for Tumor Therapy

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Background Emerging studies indicate that microbes are present in tumor cells and immune cells. Intratumoral microbiota (ITM) constitute an important component of the tumor immune microenvironment (TIME) and have an important impact on tumor progression and treatment. Objective Through the general elaboration of ITM represented by bacteria and
Fengxue Li, Lili Qiao, Xinquan Liang, Yingying Zhang, Ning Liang, Jian Xie, Guodong Deng, Yuying Hao, Pingping Hu, Xue Wu, Fangjie Ding, Can Feng, Yiming Mu, Jiandong Zhang   +13 more
wiley   +1 more source

Mathematical Modeling of the Role of Cytokines in Sindbis Virus Treatment of Glioblastoma

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Oncolytic viruses, specifically Sindbis virus (SINV), combined with cytokines show promising results in slowing glioma progression, but a quantitative understanding of their effects remains limited. In this study, we use an ordinary differential equation (ODE) model to examine the effect of adding cytokines to oncolytic SINV therapy.
Shriya Makam, Hana M. Dobrovolny
wiley   +1 more source

Activity of oncolytic vaccinia virus vectors in ovarian cancer. [PDF]

, 2012
PhDOncolytic vaccinia virus has great potential in the treatment of cancer and two engineered strains have entered clinical trials. As the advent for oncolytic vaccinia virus as an approved therapy beckons, it is critical to consider some of the ...
Whilding, Lynsey May
core  

Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A [PDF]

, 2013
© 2013 Matsumiya et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
Helen McShane (80704), Pathan, Ansar A, Stylianou, E, Lang, Z, Stephanie A. Harris (429956), Elena Stylianou (292312), Matsumiya, Magali, Griffiths Kristin, Lang Zoe, McShane Helen, Meyer, Joel, Magali Matsumiya, Griffiths, Kristin, Zoe Lang (429954), Lang, Zoe, Ansar A Pathan, Meyer, J, Angela M. Minassian (345365), Magali Matsumiya (429952), Fletcher Helen, Harris, Stephanie A, Rowland Rosalind, Meyer Joel, Kristin Griffiths (429953), Joel Meyer, Harris, SA, McShane, H, Fletcher, Helen, McShane, Helen, Minassian, Angela M, Zoe Lang, Rowland, Rosalind, Matsumiya Magali, Minassian Angela M., Angela M Minassian, Kristin Griffiths, Pathan Ansar A., Joel Meyer (429955), Helen Fletcher, Harris Stephanie A., Rowland, R, Rosalind Rowland, Matsumiya, M, Pathan, AA, Fletcher, H, Minassian, AM, Helen Fletcher (249210), Rosalind Rowland (429957), Helen McShane, Griffiths, K, Elena Stylianou, Stephanie A Harris, Ansar A. Pathan (80697), Stylianou, Elena, Stylianou Elena   +54 more
core   +1 more source

Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy

Molecular Therapy: Oncolytics, 2019
Vaccinia virus (VACV) possesses a great safety record as a smallpox vaccine and has been intensively used as an oncolytic virus against various types of cancer over the past decade.
Adrian Pelin, Johann Foloppe, Julia Petryk, Ragunath Singaravelu, Marian Hussein, Florian Gossart, Victoria A. Jennings, Lawton J. Stubbert, Madison Foster, Christopher Storbeck, Antonio Postigo, Elena Scut, Brian Laight, Michael Way, Philippe Erbs, Fabrice Le Boeuf, John C. Bell   +16 more
doaj   +1 more source